Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Myriberine A in preparation of medicines for treating or preventing yellow fever virus infection

A yellow fever virus and drug technology, applied in antiviral agents, pharmaceutical formulations, resistance to vector-borne diseases, etc., to achieve the effect of strong inhibitory activity and prominent substantive characteristics

Inactive Publication Date: 2013-08-21
NANJING ZHENGLIANG MEDICAL TECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there have been no cases reported in China, but this does not make us relax our vigilance against the virus, because China's climate and geographical environment are complex, and there are many types of mosquitoes, which have the conditions for transmission. At the same time, with the increasing frequency of international exchanges, YFV It is very likely that it will be introduced into China

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Myriberine A in preparation of medicines for treating or preventing yellow fever virus infection
  • Application of Myriberine A in preparation of medicines for treating or preventing yellow fever virus infection
  • Application of Myriberine A in preparation of medicines for treating or preventing yellow fever virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Embodiment 1: the preparation of compound Myriberine A tablet involved in the present invention:

[0013] Get 20 grams of compound Myriberine A and add 180 grams of conventional excipients for preparing tablets, mix well, and make 1000 tablets with a conventional tablet press.

Embodiment 2

[0014] Embodiment 2: the preparation of the compound Myriberine A capsule involved in the present invention:

[0015] Get 20 grams of compound Myriberine A and add conventional adjuvants such as starch 180 grams for the preparation of capsules, mix well, and make 1000 capsules.

[0016] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0018] A. Toxicity test of Myriberine A on Vero cells

[0019] Vero cells (African green monkey kidney cells) are susceptible cells to YFV.

[0020] The experimental steps are as follows:

[0021] 1: Inoculate Vero cells: Use DMEM medium containing 10% (v / v) fetal bovine serum to make a single cell suspension, inoculate 1000-10000 cells per well into a 96-well cell culture plate, and inoculate a volume of 100ul per well ;

[0022] 2: Cultivate Vero cells: at 37°C, 5% (v / v) CO2 culture conditions, culture for 2 days;

[0023] 3: Add Myriberine A: Discard the DMEM medium in each well, add 100ul to each well and dilute to the corresponding concentration with DMEM medium containing 10% (v / v) fetal bovine serum (0uM, 0.4uM, 1.2 uM, 3.7uM, 11uM, 33uM, 100uM, 300uM) Myriberine A, add 100ul of DMEM medium containing 10% (v / v) fetal bovine serum to the control well;

[0024] 4: Coloring: After 48 hours of culture, add 10ul of MTT solution to each well, continue to incubate for 4 ho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of Myriberine A in preparation of medicines for treating or preventing yellow fever virus infection. The Myriberine A can effectively inhibit yellow fever virus from multiplication, but has small toxicity to cells, can be further developed to prepare the medicines for treating diseases caused by virus infection and has a wide application prospect. The application of Myriberine A in preparation of medicines for treating or preventing yellow fever virus infection is disclosed for the first time, a framework type belongs to a brand-new framework type, the Myriberine A has an unexpected strong effect of inhibiting the yellow fever virus activity, and the revelation possibility of other compounds cannot be generated, so the application has obvious substantive features; and moreover, the application has an obvious improved effect of preventing the yellow fever virus infection.

Description

technical field [0001] The present invention relates to a new application of compound Myriberine A, in particular to the application of Myriberine A in the preparation of medicines for treating or preventing yellow fever virus infection. Background technique [0002] Yellow fever virus (YFV) is a member of the Flavivirus genus in the family Flaviviridae. Yellow fever virus causes yellow fever, an acute infectious disease. Yellow fever has been designated as a quarantine infectious disease internationally, and China has also designated it as a Class A infectious disease. In 1648, an epidemic of yellow fever was first confirmed in the weekly YUCATAN peninsula. From the 17th to the 19th century, the disease was brought to Europe and North America through transportation. Within two centuries, yellow fever became one of the most serious plagues in some parts of the United States, Africa, and Europe, causing a large number of deaths. Since the 20th century, the disease has not ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61P31/14
CPCY02A50/30
Inventor 不公告发明人
Owner NANJING ZHENGLIANG MEDICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com